U.S. markets open in 2 hours 28 minutes
  • S&P Futures

    4,260.75
    +4.75 (+0.11%)
     
  • Dow Futures

    34,185.00
    +103.00 (+0.30%)
     
  • Nasdaq Futures

    14,380.25
    +26.00 (+0.18%)
     
  • Russell 2000 Futures

    2,335.40
    +4.20 (+0.18%)
     
  • Crude Oil

    73.13
    -0.17 (-0.23%)
     
  • Gold

    1,782.70
    +6.00 (+0.34%)
     
  • Silver

    26.25
    +0.20 (+0.75%)
     
  • EUR/USD

    1.1953
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • Vix

    16.02
    -0.30 (-1.84%)
     
  • GBP/USD

    1.3896
    -0.0025 (-0.18%)
     
  • USD/JPY

    110.7750
    -0.0600 (-0.05%)
     
  • BTC-USD

    33,730.77
    +433.41 (+1.30%)
     
  • CMC Crypto 200

    806.43
    +19.82 (+2.52%)
     
  • FTSE 100

    7,119.32
    +9.35 (+0.13%)
     
  • Nikkei 225

    29,066.18
    +190.95 (+0.66%)
     

Metacrine to Present at 2021 RBC Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO, May 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 RBC Global Healthcare Conference at 5:25 p.m. ET on Tuesday, May 18, 2021.

A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations. A replay of the webcast will be archived for 30 days following the conference.

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.

Investor & Media Contact
Steve Kunszabo
Metacrine, Inc.
+1 (858) 369-7892
skunszabo@metacrine.com